India, Aug. 5 -- Ahmedabad-based Cadila Pharmaceuticals has launched Vasograin Plus, a novel, dual-action formulation designed for the acute treatment of migraines with or without aura in both adults and adolescents.

Vasograin Plus represents a major advancement in the treatment of migraine, a condition that affects millions globally and significantly influences quality of life. It is a unique therapy that combines two well-established pharmacological agents to work through complementary mechanisms, targeting both the neurological and inflammatory triggers of migraines.

It delivers rapid onset of action, longer-lasting relief, and helps reduce the likelihood of recurrence, all in a single tablet.

Vasograin Plus combines the benefits of...